51
|
Sanghavi S, Vassalotti JA. Dietary Sodium: A Therapeutic Target in the Treatment of Hypertension and CKD. J Ren Nutr 2013; 23:223-7. [DOI: 10.1053/j.jrn.2013.01.027] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2013] [Accepted: 01/20/2013] [Indexed: 01/11/2023] Open
|
52
|
Kalantarian S, Stern TA, Mansour M, Ruskin JN. Cognitive impairment associated with atrial fibrillation: a meta-analysis. Ann Intern Med 2013; 158:338-46. [PMID: 23460057 PMCID: PMC4465526 DOI: 10.7326/0003-4819-158-5-201303050-00007] [Citation(s) in RCA: 295] [Impact Index Per Article: 26.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND Atrial fibrillation (AF) has been linked with an increased risk for cognitive impairment and dementia. PURPOSE To complete a meta-analysis of studies examining the association between AF and cognitive impairment. DATA SOURCES Search of MEDLINE, PsycINFO, Cochrane Library, CINAHL, and EMBASE databases and hand search of article references. STUDY SELECTION Prospective and nonprospective studies reporting adjusted risk estimates for the association between AF and cognitive impairment. DATA EXTRACTION Two abstracters independently extracted data on study characteristics, risk estimates, methods of AF and outcome ascertainment, and methodological quality. DATA SYNTHESIS Twenty-one studies were included in the meta-analysis. Atrial fibrillation was significantly associated with a higher risk for cognitive impairment in patients with first-ever or recurrent stroke (relative risk [RR], 2.70 [95% CI, 1.82 to 4.00]) and in a broader population including patients with or without a history of stroke (RR, 1.40 [CI, 1.19 to 1.64]). The association in the latter group remained significant independent proof of clinical stroke history (RR, 1.34 [CI, 1.13 to 1.58]). However, there was significant heterogeneity among studies of the broader population (I2 = 69.4%). Limiting the analysis to prospective studies yielded similar results (RR, 1.36 [CI, 1.12 to 1.65]). Restricting the analysis to studies of dementia eliminated the significant heterogeneity (P = 0.137) but did not alter the pooled estimate substantially (RR, 1.38 [CI, 1.22 to 1.56]). LIMITATIONS There is an inherent bias because of confounding variables in observational studies. There was significant heterogeneity among included studies. CONCLUSION Evidence suggests that AF is associated with a higher risk for cognitive impairment and dementia, with or without a history of clinical stroke. Further studies are required to elucidate the association between AF and subtypes of dementia as well as the cause of cognitive impairment.
Collapse
Affiliation(s)
- Shadi Kalantarian
- Cardiac Arrhythmia Service, Massachusetts General Hospital, 55 Fruit Street, GRB 109, Boston, MA 02114, USA
| | | | | | | |
Collapse
|
53
|
Treatment of NSTEMI (Non-ST Elevation Myocardial Infarction). CURRENT EMERGENCY AND HOSPITAL MEDICINE REPORTS 2013. [DOI: 10.1007/s40138-012-0006-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
54
|
Lv J, Perkovic V, Foote CV, Craig ME, Craig JC, Strippoli GFM. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev 2012; 12:CD004136. [PMID: 23235603 DOI: 10.1002/14651858.cd004136.pub3] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
BACKGROUND Various blood pressure-lowering agents, and particularly inhibitors of the renin-angiotensin system (RAS), are widely used for people with diabetes to prevent the onset of diabetic kidney disease (DKD) and adverse cardiovascular outcomes. This is an update of a Cochrane review first published in 2003 and updated in 2005. OBJECTIVES This systematic review aimed to assess the benefits and harms of blood pressure lowering agents in people with diabetes mellitus and a normal amount of albumin in the urine (normoalbuminuria). SEARCH METHODS In January 2011 we searched the Cochrane Renal Group's Specialised Register through contact with the Trials Search Co-ordinator. SELECTION CRITERIA Randomised controlled trials (RCTs) comparing any antihypertensive agent with placebo or another agent in hypertensive or normotensive patients with diabetes and no kidney disease (albumin excretion rate < 30 mg/d) were included. DATA COLLECTION AND ANALYSIS Two investigators independently extracted data on kidney and other patient-relevant outcomes (all-cause mortality and serious cardiovascular events), and assessed study quality. Analysis was by a random effects model was applied to analyse results which were expressed as risk ratio (RR) and 95% confidence intervals (CI). MAIN RESULTS We identified 26 studies that enrolling 61,264 participants. Angiotensin-converting enzyme inhibitors (ACEi) reduced the risk of new onset of microalbuminuria, macroalbuminuria or both when compared to placebo (8 studies, 11,906 patients: RR 0.71, 95% CI 0.56 to 0.89), with similar benefits in people with and without hypertension (P = 0.74), and when compared to calcium channel blockers (5 studies, 1253 participants: RR 0.60, 95% CI 0.42 to 0.85). ACEi reduced the risk of death when compared to placebo (6 studies, 11,350 participants: RR 0.84, 95% CI 0.73 to 0.97). No effect was observed for angiotensin receptor blockers (ARB) when compared to placebo for new microalbuminuria, macroalbuminuria or both (5 studies, 7653 participants: RR 0.90, 95% CI 0.68 to 1.19) or death (5 studies, 7653 participants: RR 1.12, 95% CI 0.88 to 1.41); however, meta-regression suggested possible benefits from ARB for preventing kidney disease in high risk patients. There was a trend towards benefit from use of combined ACEi and ARB for prevention of DKD compared with ACEi alone (2 studies, 4171 participants: RR 0.88, 95% CI 0.78 to 1.00).The risk of cough was significantly increased with ACEi when compared to placebo (6 studies, 11,791 patients: RR 1.84, 95% CI 1.24 to 2.72), however there was no significant difference in the risk of headache or hyperkalaemia. There was no significant difference in the risk of cough, headache or hyperkalaemia when ARB was to placebo. On average risk of bias was judged to be either low (27% to 69%) or unclear (i.e. no information available) (8% to 73%). Blinding of participants, incomplete outcome data and selective reporting were judged to be high in 23%, 31% and 31% of studies, respectively. AUTHORS' CONCLUSIONS ACEi were found to prevent new onset DKD and death in normoalbuminuric people with diabetes, and could therefore be used in this population. More data are needed to clarify the role of ARB and other drug classes in preventing DKD.
Collapse
Affiliation(s)
- Jicheng Lv
- Renal andMetabolic Division, The George Institute for Global Health, Camperdown, Australia
| | | | | | | | | | | |
Collapse
|
55
|
Dehghan M, Mente A, Teo KK, Gao P, Sleight P, Dagenais G, Avezum A, Probstfield JL, Dans T, Yusuf S. Relationship Between Healthy Diet and Risk of Cardiovascular Disease Among Patients on Drug Therapies for Secondary Prevention. Circulation 2012; 126:2705-12. [PMID: 23212996 DOI: 10.1161/circulationaha.112.103234] [Citation(s) in RCA: 127] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background—
Diet quality is strongly related to cardiovascular disease (CVD) incidence, but little is known about its impact on CVD events in older people at high risk of CVD and receiving effective drugs for secondary prevention. This study assessed the association between diet quality and CVD events in a large population of subjects from 40 countries with CVD or diabetes mellitus with end-organ damage receiving proven medications.
Methods and Results—
Overall, 31 546 women and men 66.5±6.2 years of age enrolled in 2 randomized trials, the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET) and the Telmisartan Randomized Assessment Study in ACEI Intolerant Subjects With Cardiovascular Disease (TRANSCEND), were studied. We used 2 dietary indexes: the modified Alternative Healthy Eating Index and the Diet Risk Score. The association between diet quality and the primary composite outcome of CV death, myocardial infarction, stroke, or congestive heart failure was assessed with Cox proportional hazard regression with adjustment for age, sex, trial enrollment allocation, region, and other known confounders. During the 56-month follow-up, there were 5190 events. Patients in the healthier quintiles of modified Alternative Healthy Eating Index scores had a significantly lower risk of CVD (hazard ratio, 0.78; 95% confidence interval, 0.71–0.87, top versus lowest quintile of modified Alternative Healthy Eating Index). The reductions in risk for CV death, myocardial infarction, and stroke were 35%, 14%, and 19%, respectively. The protective association was consistent regardless of whether patients were receiving proven drugs.
Conclusions—
A higher-quality diet was associated with a lower risk of recurrent CVD events among people ≥55 years of age with CVD or diabetes mellitus. Highlighting the importance of healthy eating by health professionals would substantially reduce CVD recurrence and save lives globally.
Clinical Trial Registration—
URL:
http://www.clinicaltrials.gov
. Unique identifier: NCT00153101.
Collapse
Affiliation(s)
- Mahshid Dehghan
- From the Population Health Research Institute (M.D., A.M., K.K.T., P.G., S.Y.) and Department of Clinical Epidemiology and Biostatistics (A.M.), McMaster University, Hamilton, ON, Canada; Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, UK (P.S.); Laval University Heart and Lung Institute, Quebec, QC, Canada (G.D.); Research Division, Dante Pazzanese Institute of Cardiology, São Paulo, Brazil (A.A.); University of Washington, School of Medicine, Seattle (J.L.P.); and Section of
| | - Andrew Mente
- From the Population Health Research Institute (M.D., A.M., K.K.T., P.G., S.Y.) and Department of Clinical Epidemiology and Biostatistics (A.M.), McMaster University, Hamilton, ON, Canada; Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, UK (P.S.); Laval University Heart and Lung Institute, Quebec, QC, Canada (G.D.); Research Division, Dante Pazzanese Institute of Cardiology, São Paulo, Brazil (A.A.); University of Washington, School of Medicine, Seattle (J.L.P.); and Section of
| | - Koon K. Teo
- From the Population Health Research Institute (M.D., A.M., K.K.T., P.G., S.Y.) and Department of Clinical Epidemiology and Biostatistics (A.M.), McMaster University, Hamilton, ON, Canada; Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, UK (P.S.); Laval University Heart and Lung Institute, Quebec, QC, Canada (G.D.); Research Division, Dante Pazzanese Institute of Cardiology, São Paulo, Brazil (A.A.); University of Washington, School of Medicine, Seattle (J.L.P.); and Section of
| | - Peggy Gao
- From the Population Health Research Institute (M.D., A.M., K.K.T., P.G., S.Y.) and Department of Clinical Epidemiology and Biostatistics (A.M.), McMaster University, Hamilton, ON, Canada; Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, UK (P.S.); Laval University Heart and Lung Institute, Quebec, QC, Canada (G.D.); Research Division, Dante Pazzanese Institute of Cardiology, São Paulo, Brazil (A.A.); University of Washington, School of Medicine, Seattle (J.L.P.); and Section of
| | - Peter Sleight
- From the Population Health Research Institute (M.D., A.M., K.K.T., P.G., S.Y.) and Department of Clinical Epidemiology and Biostatistics (A.M.), McMaster University, Hamilton, ON, Canada; Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, UK (P.S.); Laval University Heart and Lung Institute, Quebec, QC, Canada (G.D.); Research Division, Dante Pazzanese Institute of Cardiology, São Paulo, Brazil (A.A.); University of Washington, School of Medicine, Seattle (J.L.P.); and Section of
| | - Gilles Dagenais
- From the Population Health Research Institute (M.D., A.M., K.K.T., P.G., S.Y.) and Department of Clinical Epidemiology and Biostatistics (A.M.), McMaster University, Hamilton, ON, Canada; Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, UK (P.S.); Laval University Heart and Lung Institute, Quebec, QC, Canada (G.D.); Research Division, Dante Pazzanese Institute of Cardiology, São Paulo, Brazil (A.A.); University of Washington, School of Medicine, Seattle (J.L.P.); and Section of
| | - Alvaro Avezum
- From the Population Health Research Institute (M.D., A.M., K.K.T., P.G., S.Y.) and Department of Clinical Epidemiology and Biostatistics (A.M.), McMaster University, Hamilton, ON, Canada; Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, UK (P.S.); Laval University Heart and Lung Institute, Quebec, QC, Canada (G.D.); Research Division, Dante Pazzanese Institute of Cardiology, São Paulo, Brazil (A.A.); University of Washington, School of Medicine, Seattle (J.L.P.); and Section of
| | - Jeffrey L. Probstfield
- From the Population Health Research Institute (M.D., A.M., K.K.T., P.G., S.Y.) and Department of Clinical Epidemiology and Biostatistics (A.M.), McMaster University, Hamilton, ON, Canada; Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, UK (P.S.); Laval University Heart and Lung Institute, Quebec, QC, Canada (G.D.); Research Division, Dante Pazzanese Institute of Cardiology, São Paulo, Brazil (A.A.); University of Washington, School of Medicine, Seattle (J.L.P.); and Section of
| | - Tony Dans
- From the Population Health Research Institute (M.D., A.M., K.K.T., P.G., S.Y.) and Department of Clinical Epidemiology and Biostatistics (A.M.), McMaster University, Hamilton, ON, Canada; Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, UK (P.S.); Laval University Heart and Lung Institute, Quebec, QC, Canada (G.D.); Research Division, Dante Pazzanese Institute of Cardiology, São Paulo, Brazil (A.A.); University of Washington, School of Medicine, Seattle (J.L.P.); and Section of
| | - Salim Yusuf
- From the Population Health Research Institute (M.D., A.M., K.K.T., P.G., S.Y.) and Department of Clinical Epidemiology and Biostatistics (A.M.), McMaster University, Hamilton, ON, Canada; Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, UK (P.S.); Laval University Heart and Lung Institute, Quebec, QC, Canada (G.D.); Research Division, Dante Pazzanese Institute of Cardiology, São Paulo, Brazil (A.A.); University of Washington, School of Medicine, Seattle (J.L.P.); and Section of
| |
Collapse
|
56
|
Mancia G, Parati G, Bilo G, Gao P, Fagard R, Redon J, Czuriga I, Polák M, Ribeiro JM, Sanchez R, Trimarco B, Verdecchia P, van Mieghem W, Teo K, Sleight P, Yusuf S. Ambulatory Blood Pressure Values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET). Hypertension 2012; 60:1400-6. [DOI: 10.1161/hypertensionaha.112.199562] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
In the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial, telmisartan (T; 80 mg daily) and ramipril (R; 10 mg daily) caused similar clinic blood pressure (BP) reductions, with a similar incidence of cardiovascular and renal events. The R+T combination lowered clinic BP somewhat more with no further cardiovascular or renal protection. The aim of this substudy was to see whether these clinic BP changes reflected the changes of 24-hour BP, a BP with a better prognostic value. In 422 patients in whom 24-hour BP monitoring was performed either before or after 6 to 24 months of treatment, demographic and clinical characteristics were similar in the 3 treated groups. Twenty-four-hour systolic BP was similarly reduced by R (−2.0 mm Hg) and T (−2.1 mm Hg), whereas the reduction was more than twice as large in the T+R group (−5.3 mm Hg), which showed a lower on-treatment 24-hour BP also in additional patients (n=408) in whom ambulatory BP was performed only on-treatment. Twenty-four-hour systolic BP was ≈14 mm Hg lower than clinic systolic BP at baseline, whereas during treatment the 2 values became progressively closer as clinic systolic BP was more tightly controlled and superimposable when clinic systolic BP was <120 mm Hg. Similar results were obtained for diastolic BP. These findings provide evidence on the relationship of clinic and ambulatory BP target drug treatment. They also show that in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial, failure of the R+T combination to enhance cardiovascular and renal protection was not because of inability to more effectively control daily life BP.
Collapse
Affiliation(s)
- Giuseppe Mancia
- From the Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Monza, Italy (M.G., P.G.); Istituto Auxologico Italiano, Milan, Italy (M.G., P.G., B.G.); Population Health Research Institute, Hamilton, Ontario, Canada (G.P., T.K., Y.S.); University of Leuven, Leuven, Belgium (F.R.); University of Valencia, Valencia, Spain (R.J.); University of Debrecem, Debrecem, Hungary (C.I.); Medeurop, Praha, Czech Republic (P.M.); Department of Cardiology, Felicio Rocho Hospital, Belo
| | - Gianfranco Parati
- From the Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Monza, Italy (M.G., P.G.); Istituto Auxologico Italiano, Milan, Italy (M.G., P.G., B.G.); Population Health Research Institute, Hamilton, Ontario, Canada (G.P., T.K., Y.S.); University of Leuven, Leuven, Belgium (F.R.); University of Valencia, Valencia, Spain (R.J.); University of Debrecem, Debrecem, Hungary (C.I.); Medeurop, Praha, Czech Republic (P.M.); Department of Cardiology, Felicio Rocho Hospital, Belo
| | - Grzegorz Bilo
- From the Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Monza, Italy (M.G., P.G.); Istituto Auxologico Italiano, Milan, Italy (M.G., P.G., B.G.); Population Health Research Institute, Hamilton, Ontario, Canada (G.P., T.K., Y.S.); University of Leuven, Leuven, Belgium (F.R.); University of Valencia, Valencia, Spain (R.J.); University of Debrecem, Debrecem, Hungary (C.I.); Medeurop, Praha, Czech Republic (P.M.); Department of Cardiology, Felicio Rocho Hospital, Belo
| | - Peggy Gao
- From the Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Monza, Italy (M.G., P.G.); Istituto Auxologico Italiano, Milan, Italy (M.G., P.G., B.G.); Population Health Research Institute, Hamilton, Ontario, Canada (G.P., T.K., Y.S.); University of Leuven, Leuven, Belgium (F.R.); University of Valencia, Valencia, Spain (R.J.); University of Debrecem, Debrecem, Hungary (C.I.); Medeurop, Praha, Czech Republic (P.M.); Department of Cardiology, Felicio Rocho Hospital, Belo
| | - Robert Fagard
- From the Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Monza, Italy (M.G., P.G.); Istituto Auxologico Italiano, Milan, Italy (M.G., P.G., B.G.); Population Health Research Institute, Hamilton, Ontario, Canada (G.P., T.K., Y.S.); University of Leuven, Leuven, Belgium (F.R.); University of Valencia, Valencia, Spain (R.J.); University of Debrecem, Debrecem, Hungary (C.I.); Medeurop, Praha, Czech Republic (P.M.); Department of Cardiology, Felicio Rocho Hospital, Belo
| | - Josep Redon
- From the Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Monza, Italy (M.G., P.G.); Istituto Auxologico Italiano, Milan, Italy (M.G., P.G., B.G.); Population Health Research Institute, Hamilton, Ontario, Canada (G.P., T.K., Y.S.); University of Leuven, Leuven, Belgium (F.R.); University of Valencia, Valencia, Spain (R.J.); University of Debrecem, Debrecem, Hungary (C.I.); Medeurop, Praha, Czech Republic (P.M.); Department of Cardiology, Felicio Rocho Hospital, Belo
| | - Istvan Czuriga
- From the Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Monza, Italy (M.G., P.G.); Istituto Auxologico Italiano, Milan, Italy (M.G., P.G., B.G.); Population Health Research Institute, Hamilton, Ontario, Canada (G.P., T.K., Y.S.); University of Leuven, Leuven, Belgium (F.R.); University of Valencia, Valencia, Spain (R.J.); University of Debrecem, Debrecem, Hungary (C.I.); Medeurop, Praha, Czech Republic (P.M.); Department of Cardiology, Felicio Rocho Hospital, Belo
| | - Martin Polák
- From the Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Monza, Italy (M.G., P.G.); Istituto Auxologico Italiano, Milan, Italy (M.G., P.G., B.G.); Population Health Research Institute, Hamilton, Ontario, Canada (G.P., T.K., Y.S.); University of Leuven, Leuven, Belgium (F.R.); University of Valencia, Valencia, Spain (R.J.); University of Debrecem, Debrecem, Hungary (C.I.); Medeurop, Praha, Czech Republic (P.M.); Department of Cardiology, Felicio Rocho Hospital, Belo
| | - Josè M. Ribeiro
- From the Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Monza, Italy (M.G., P.G.); Istituto Auxologico Italiano, Milan, Italy (M.G., P.G., B.G.); Population Health Research Institute, Hamilton, Ontario, Canada (G.P., T.K., Y.S.); University of Leuven, Leuven, Belgium (F.R.); University of Valencia, Valencia, Spain (R.J.); University of Debrecem, Debrecem, Hungary (C.I.); Medeurop, Praha, Czech Republic (P.M.); Department of Cardiology, Felicio Rocho Hospital, Belo
| | - Ramiro Sanchez
- From the Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Monza, Italy (M.G., P.G.); Istituto Auxologico Italiano, Milan, Italy (M.G., P.G., B.G.); Population Health Research Institute, Hamilton, Ontario, Canada (G.P., T.K., Y.S.); University of Leuven, Leuven, Belgium (F.R.); University of Valencia, Valencia, Spain (R.J.); University of Debrecem, Debrecem, Hungary (C.I.); Medeurop, Praha, Czech Republic (P.M.); Department of Cardiology, Felicio Rocho Hospital, Belo
| | - Bruno Trimarco
- From the Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Monza, Italy (M.G., P.G.); Istituto Auxologico Italiano, Milan, Italy (M.G., P.G., B.G.); Population Health Research Institute, Hamilton, Ontario, Canada (G.P., T.K., Y.S.); University of Leuven, Leuven, Belgium (F.R.); University of Valencia, Valencia, Spain (R.J.); University of Debrecem, Debrecem, Hungary (C.I.); Medeurop, Praha, Czech Republic (P.M.); Department of Cardiology, Felicio Rocho Hospital, Belo
| | - Paolo Verdecchia
- From the Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Monza, Italy (M.G., P.G.); Istituto Auxologico Italiano, Milan, Italy (M.G., P.G., B.G.); Population Health Research Institute, Hamilton, Ontario, Canada (G.P., T.K., Y.S.); University of Leuven, Leuven, Belgium (F.R.); University of Valencia, Valencia, Spain (R.J.); University of Debrecem, Debrecem, Hungary (C.I.); Medeurop, Praha, Czech Republic (P.M.); Department of Cardiology, Felicio Rocho Hospital, Belo
| | - Walter van Mieghem
- From the Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Monza, Italy (M.G., P.G.); Istituto Auxologico Italiano, Milan, Italy (M.G., P.G., B.G.); Population Health Research Institute, Hamilton, Ontario, Canada (G.P., T.K., Y.S.); University of Leuven, Leuven, Belgium (F.R.); University of Valencia, Valencia, Spain (R.J.); University of Debrecem, Debrecem, Hungary (C.I.); Medeurop, Praha, Czech Republic (P.M.); Department of Cardiology, Felicio Rocho Hospital, Belo
| | - Koon Teo
- From the Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Monza, Italy (M.G., P.G.); Istituto Auxologico Italiano, Milan, Italy (M.G., P.G., B.G.); Population Health Research Institute, Hamilton, Ontario, Canada (G.P., T.K., Y.S.); University of Leuven, Leuven, Belgium (F.R.); University of Valencia, Valencia, Spain (R.J.); University of Debrecem, Debrecem, Hungary (C.I.); Medeurop, Praha, Czech Republic (P.M.); Department of Cardiology, Felicio Rocho Hospital, Belo
| | - Peter Sleight
- From the Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Monza, Italy (M.G., P.G.); Istituto Auxologico Italiano, Milan, Italy (M.G., P.G., B.G.); Population Health Research Institute, Hamilton, Ontario, Canada (G.P., T.K., Y.S.); University of Leuven, Leuven, Belgium (F.R.); University of Valencia, Valencia, Spain (R.J.); University of Debrecem, Debrecem, Hungary (C.I.); Medeurop, Praha, Czech Republic (P.M.); Department of Cardiology, Felicio Rocho Hospital, Belo
| | - Salim Yusuf
- From the Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Monza, Italy (M.G., P.G.); Istituto Auxologico Italiano, Milan, Italy (M.G., P.G., B.G.); Population Health Research Institute, Hamilton, Ontario, Canada (G.P., T.K., Y.S.); University of Leuven, Leuven, Belgium (F.R.); University of Valencia, Valencia, Spain (R.J.); University of Debrecem, Debrecem, Hungary (C.I.); Medeurop, Praha, Czech Republic (P.M.); Department of Cardiology, Felicio Rocho Hospital, Belo
| |
Collapse
|
57
|
Barzilay JI, Gao P, Clase CM, Mente A, Mann JFE, Sleight P, Yusuf S, Teo KK. Albuminuria and rapid loss of GFR and risk of new hip and pelvic fractures. Clin J Am Soc Nephrol 2012. [PMID: 23184565 DOI: 10.2215/cjn.06640712] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
BACKGROUND AND OBJECTIVES The microvascular circulation plays an important role in bone health. This study examines whether albuminuria, a marker of renal microvascular disease, is associated with incident hip and pelvic fractures. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS This study reanalyzed data from the Ongoing Telmisartan Alone and in combination with Ramipril Global End Point Trial/Telmisartan Randomized Assessment Study in Angiotensin-Converting Enzyme Intolerant Subjects with Cardiovascular Disease trials, which examined the impact of renin angiotensin system blockade on cardiovascular outcomes (n=28,601). Albuminuria was defined as an albumin-to-creatinine ratio≥30 mg/g (n=4597). Cox proportional hazards models were used to determine the association of albuminuria with fracture risk adjusted for known risk factors for fractures, estimated GFR, and rapid decline in estimated GFR (≥5%/yr). RESULTS There were 276 hip and pelvic fractures during a mean of 4.6 years of follow-up. Participants with baseline albuminuria had a significantly increased risk of fracture compared with participants without albuminuria (unadjusted hazard ratio=1.62 [1.22, 2.15], P<0.001; adjusted hazard ratio=1.36 [1.01, 1.84], P=0.05). A dose-dependent relationship was observed, with macroalbuminuria having a large fracture risk (unadjusted hazard ratio=2.01 [1.21, 3.35], P=0.007; adjusted hazard ratio=1.71 [1.007, 2.91], P=0.05) and microalbuminuria associating with borderline or no statistical significance (unadjusted hazard ratio=1.52 [1.10, 2.09], P=0.01; adjusted hazard ratio=1.28 [0.92, 1.78], P=0.15). Estimated GFR was not a predictor of fracture in any model, but rapid loss of estimated GFR over the first 2 years of follow-up predicted subsequent fracture (adjusted hazard ratio=1.47 [1.05, 2.04], P=0.02). CONCLUSIONS Albuminuria, especially macroalbuminuria, and rapid decline of estimated GFR predict hip and pelvic fractures. These findings support a theoretical model of a relationship between underlying causes of microalbuminuria and bone disease.
Collapse
Affiliation(s)
- Joshua I Barzilay
- Division of Endocrinology, Emory University School of Medicine, Atlanta, Georgia, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
58
|
Di Legge S, Koch G, Diomedi M, Stanzione P, Sallustio F. Stroke prevention: managing modifiable risk factors. Stroke Res Treat 2012; 2012:391538. [PMID: 23213626 PMCID: PMC3504482 DOI: 10.1155/2012/391538] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2012] [Accepted: 10/08/2012] [Indexed: 12/12/2022] Open
Abstract
Prevention plays a crucial role in counteracting morbidity and mortality related to ischemic stroke. It has been estimated that 50% of stroke are preventable through control of modifiable risk factors and lifestyle changes. Antihypertensive treatment is recommended for both prevention of recurrent stroke and other vascular events. The use of antiplatelets and statins has been shown to reduce the risk of recurrent stroke and other vascular events. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are indicated in stroke prevention because they also promote vascular health. Effective secondary-prevention strategies for selected patients include carotid revascularization for high-grade carotid stenosis and vitamin K antagonist treatment for atrial fibrillation. The results of recent clinical trials investigating new anticoagulants (factor Xa inhibitors and direct thrombin inhibitors) clearly indicate alternative strategies in stroke prevention for patients with atrial fibrillation. This paper describes the current landscape and developments in stroke prevention with special reference to medical treatment in secondary prevention of ischemic stroke.
Collapse
Affiliation(s)
- Silvia Di Legge
- Stroke Unit, Department of Neuroscience, University of Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
| | - Giacomo Koch
- Stroke Unit, Department of Neuroscience, University of Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
- Santa Lucia Foundation, IRCCS, Viale Ardeatina 306, 00134 Rome, Italy
| | - Marina Diomedi
- Stroke Unit, Department of Neuroscience, University of Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
| | - Paolo Stanzione
- Stroke Unit, Department of Neuroscience, University of Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
- Santa Lucia Foundation, IRCCS, Viale Ardeatina 306, 00134 Rome, Italy
| | - Fabrizio Sallustio
- Stroke Unit, Department of Neuroscience, University of Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
- Santa Lucia Foundation, IRCCS, Viale Ardeatina 306, 00134 Rome, Italy
| |
Collapse
|
59
|
Verdecchia P, Angeli F, Gentile G, Mazzotta G, Reboldi G. Telmisartan for the reduction of cardiovascular morbidity and mortality. Expert Rev Clin Pharmacol 2012; 4:151-61. [PMID: 22115399 DOI: 10.1586/ecp.10.141] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Cardiovascular disease (CVD) poses a significant healthcare and economic burden on societies and individuals. Angiotensin II is a key component of the renin-angiotensin system that plays a central role in atherosclerotic mechanisms that contribute to CVD. Renin-angiotensin system blockers are widely used to reduce cardiovascular (CV) risk owing to their potential both to lower blood pressure, a CV risk factor, and to attenuate the atherosclerotic disease process directly. Telmisartan has a number of pharmacological properties that distinguish it from other angiotensin II receptor blockers (ARBs) - the longest plasma half-life, highest lipophilicity and strongest receptor binding affinity in class. The ONTARGET(®) trial showed that telmisartan is as effective as ramipril in reducing CV morbidity (including myocardial infarction and stroke) and mortality in a broad range of patients at increased CV risk. Evidence from other ARBs remains largely restricted to patients with heart failure, diabetic nephropathy or specific subsets of hypertensive patients. Telmisartan is, therefore, the only ARB with a broad indication for CV risk reduction in patients with atherothrombotic disease or diabetes with end-organ damage.
Collapse
Affiliation(s)
- Paolo Verdecchia
- Unità Operativa Complessa di Medicina, Ospedale di Assisi, Via Valentin Muller, 06081 Assisi, Italy.
| | | | | | | | | |
Collapse
|
60
|
Kappert K, Böhm M, Schmieder R, Schumacher H, Teo K, Yusuf S, Sleight P, Unger T. Impact of Sex on Cardiovascular Outcome in Patients at High Cardiovascular Risk. Circulation 2012; 126:934-41. [DOI: 10.1161/circulationaha.111.086660] [Citation(s) in RCA: 74] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background—
Epidemiological data suggest that sex independently contributes to cardiovascular risk. Clinical trials are often hampered by the enrollment of few female patients.
Methods and Results—
The Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET) and the parallel Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND) included a large proportion of female patients (9378 female versus 22 168 male patients). Differences in male and female patients enrolled in ONTARGET/TRANSCEND were analyzed for the primary 4-fold end point (composite of cardiovascular death, myocardial infarction, stroke, or admission to hospital for heart failure), a secondary 3-fold end point (cardiovascular death, myocardial infarction, stroke), and individual components of the primary composite. Baseline characteristics included age, ethnicity, body mass index, physical activity, tobacco use, alcohol consumption, formal education, clinical diagnosis for study entry, patient history, and concomitant medication. Patients were followed up until death or the end of the study (median, 56 months). Compared with male patients, female patients had a 19% significantly lower risk for the 4-fold end point and 21% for the 3-fold end point (after adjustment for study, treatment, and the above baseline values). Similarly, the adjusted risk for cardiovascular death (17%) and myocardial infarction (22%), but not for stroke and hospitalization for heart failure, was also significantly lower in women. Diabetic female patients were characterized by a higher risk for acute myocardial infarction compared with diabetic male patients, whereas alcohol consumption resulted in significantly lower risk in women.
Conclusions—
In our analysis made up of 70.3% male and 29.7% female patients, an ≈20% lower risk for the combined cardiovascular end points in female patients was observed despite treatment with cardioprotective agents. This difference was driven primarily by a significantly lower incidence of myocardial infarction. Thus, we demonstrate in a large interventional trial that sex greatly affects the occurrence of cardiovascular events in patients with vascular disease or high-risk diabetes mellitus.
Clinical Trial Registration—
URL:
http://www.clinicaltrials.gov
. Unique identifier: NCT00153101.
Collapse
Affiliation(s)
- Kai Kappert
- From the Center for Cardiovascular Research/CCC, and Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité–University Medicine Berlin, Berlin, Germany (K.K.); CARIM–School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands (T.U.); Klinik für Innere Medizin III, University Clinic of the Saarland, Homburg/Saar, Germany (M.B.); Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, Germany (R.S.); Boehringer
| | - Michael Böhm
- From the Center for Cardiovascular Research/CCC, and Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité–University Medicine Berlin, Berlin, Germany (K.K.); CARIM–School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands (T.U.); Klinik für Innere Medizin III, University Clinic of the Saarland, Homburg/Saar, Germany (M.B.); Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, Germany (R.S.); Boehringer
| | - Roland Schmieder
- From the Center for Cardiovascular Research/CCC, and Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité–University Medicine Berlin, Berlin, Germany (K.K.); CARIM–School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands (T.U.); Klinik für Innere Medizin III, University Clinic of the Saarland, Homburg/Saar, Germany (M.B.); Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, Germany (R.S.); Boehringer
| | - Helmut Schumacher
- From the Center for Cardiovascular Research/CCC, and Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité–University Medicine Berlin, Berlin, Germany (K.K.); CARIM–School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands (T.U.); Klinik für Innere Medizin III, University Clinic of the Saarland, Homburg/Saar, Germany (M.B.); Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, Germany (R.S.); Boehringer
| | - Koon Teo
- From the Center for Cardiovascular Research/CCC, and Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité–University Medicine Berlin, Berlin, Germany (K.K.); CARIM–School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands (T.U.); Klinik für Innere Medizin III, University Clinic of the Saarland, Homburg/Saar, Germany (M.B.); Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, Germany (R.S.); Boehringer
| | - Salim Yusuf
- From the Center for Cardiovascular Research/CCC, and Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité–University Medicine Berlin, Berlin, Germany (K.K.); CARIM–School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands (T.U.); Klinik für Innere Medizin III, University Clinic of the Saarland, Homburg/Saar, Germany (M.B.); Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, Germany (R.S.); Boehringer
| | - Peter Sleight
- From the Center for Cardiovascular Research/CCC, and Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité–University Medicine Berlin, Berlin, Germany (K.K.); CARIM–School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands (T.U.); Klinik für Innere Medizin III, University Clinic of the Saarland, Homburg/Saar, Germany (M.B.); Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, Germany (R.S.); Boehringer
| | - Thomas Unger
- From the Center for Cardiovascular Research/CCC, and Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité–University Medicine Berlin, Berlin, Germany (K.K.); CARIM–School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands (T.U.); Klinik für Innere Medizin III, University Clinic of the Saarland, Homburg/Saar, Germany (M.B.); Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, Germany (R.S.); Boehringer
| |
Collapse
|
61
|
Kamato D, Burch ML, Osman N, Zheng W, Little PJ. Therapeutic implications of endothelin and thrombin G-protein-coupled receptor transactivation of tyrosine and serine/threonine kinase cell surface receptors. J Pharm Pharmacol 2012; 65:465-73. [DOI: 10.1111/j.2042-7158.2012.01577.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Abstract
Objectives
This review discusses the latest developments in G protein coupled receptor (GPCR) signalling related to the transactivation of cell surface protein kinase receptors and the therapeutic implications.
Key findings
Multiple GPCRs have been known to transactivate protein tyrosine kinase receptors for almost two decades. More recently it has been discovered that GPCRs can also transactivate protein serine/threonine kinase receptors such as that for transforming growth factor (TGF)-β. Using the model of proteoglycan synthesis and glycosaminoglycan elongation in human vascular smooth muscle cells which is a component of an in vitro model of atherosclerosis, the dual tyrosine and serine/threonine kinase receptor transactivation pathways appear to account for all of the response to the agonists, endothelin and thrombin.
Summary
The broadening of the paradigm of GPCR receptor transactivation explains the broad range of activities of these receptors and also the efficacy of GPCR antagonists in cardiovascular therapeutics. Deciphering the mechanisms of transactivation with the aim of identifying a common therapeutic target remains the next challenge.
Collapse
Affiliation(s)
- Danielle Kamato
- Discipline of Pharmacy, School of Medical Sciences, Australia
- Diabetes Complications Group, Metabolism, Exercise and Disease Program, Health Innovations Research Institute, RMIT University, Melbourne, Australia
| | - Micah L Burch
- Diabetes Complications Group, Metabolism, Exercise and Disease Program, Health Innovations Research Institute, RMIT University, Melbourne, Australia
- Department of Medicine, Monash University School of Medicine (Central and Eastern Clinical School, Alfred Health), Prahran VIC, Australia
| | - Narin Osman
- Discipline of Pharmacy, School of Medical Sciences, Australia
- Diabetes Complications Group, Metabolism, Exercise and Disease Program, Health Innovations Research Institute, RMIT University, Melbourne, Australia
| | - Wenhua Zheng
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Centre and School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China
| | - Peter J Little
- Discipline of Pharmacy, School of Medical Sciences, Australia
- Diabetes Complications Group, Metabolism, Exercise and Disease Program, Health Innovations Research Institute, RMIT University, Melbourne, Australia
- Department of Medicine, Monash University School of Medicine (Central and Eastern Clinical School, Alfred Health), Prahran VIC, Australia
| |
Collapse
|
62
|
Cao Z, Cooper ME. Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetes. Acta Diabetol 2012; 49:243-54. [PMID: 21947383 DOI: 10.1007/s00592-011-0328-3] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/14/2011] [Accepted: 09/06/2011] [Indexed: 12/17/2022]
Abstract
Cardiovascular disease is the predominant cause of morbidity in people with type 2 diabetes. Hypertension frequently coexists with diabetes and substantially increases the risk of developing end-organ damage. Controlling hypertension in patients with diabetes is therefore critical to reducing microvascular and macrovascular complications. Agents that block the renin-angiotensin system are increasingly used in patients with diabetes based on their cardiovascular and renoprotective effects, in addition to their direct effects on reducing blood pressure. Telmisartan, an angiotensin II receptor blocker (ARB), has a number of distinguishing pharmacological properties such as having the longest half-life and highest lipophilicity in its class. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET(®)) trial showed that telmisartan reduces cardiovascular morbidity (including myocardial infarction and stroke) in subjects with a broad spectrum of cardiovascular risk factors, including type 2 diabetes. Telmisartan is the only ARB indicated for the reduction of cardiovascular morbidity in patients with diabetes and end-organ damage, as well as in patients without diabetes but with a history of coronary artery disease, peripheral artery disease, or previous stroke. Trials of telmisartan in patients with diabetes and varying degrees of nephropathy also suggest that this drug can slow the progression of renal disease, an effect that appears to be at least partly independent of reduction in blood pressure. Telmisartan is therefore an important therapeutic option for optimizing cardiovascular and renal protection in the type 2 diabetic population.
Collapse
Affiliation(s)
- Zemin Cao
- Diabetes Division, Baker IDI Heart and Diabetes Institute, Melbourne, Australia
| | | |
Collapse
|
63
|
Valsartan and Telmisartan Abrogate Angiotensin II–induced Downregulation of ABCA1 Expression Via AT1 Receptor, Rather than AT2 Receptor or PPARγ Activation. J Cardiovasc Pharmacol 2012; 59:570-5. [DOI: 10.1097/fjc.0b013e31824fc5e3] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
64
|
Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, Fagard R, Verdecchia P, Weber M, Böhm M, Williams B, Yusoff K, Teo K, Yusuf S. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol 2012; 59:74-83. [PMID: 22192672 DOI: 10.1016/j.jacc.2011.09.040] [Citation(s) in RCA: 124] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/23/2011] [Revised: 09/15/2011] [Accepted: 09/19/2011] [Indexed: 11/24/2022]
Abstract
OBJECTIVES We sought to determine whether the blood pressure (BP) levels at which cardiovascular (CV) protection is achieved differ between diabetic and nondiabetic patients from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). BACKGROUND Greater absolute benefits of BP reductions have been claimed for diabetic as compared with nondiabetic patients. METHODS A total of 25,584 patients (9,603 diabetic), older than 55 years, at high CV risk were randomized to ramipril, telmisartan, or both and observed for 4.6 years. We pooled the treatment arms to examine the relationships between BP and the primary composite outcome (CV death, nonfatal myocardial infarction or stroke, or hospitalized heart failure) and its components. RESULTS The primary outcome occurred in 1,938 (20.2%) diabetic patients and in 2,276 (14.2%) nondiabetic patients. Compared with nondiabetic patients, diabetic patients had a significantly higher risk for the primary endpoint (hazard ratio [HR]: 1.48; 95% confidence interval [CI]: 1.38 to 1.57) and CV death (HR: 1.56; 95% CI: 1.42 to 1.71); myocardial infarction (HR: 1.30 (95% CI: 1.17 to 1.46); stroke (HR: 1.39; 95% CI: 1.23 to 1.56); and congestive heart failure hospitalization (HR: 2.06; 95% CI: 1.82 to 2.32). The CV risk was significantly higher in diabetic than in nondiabetic patients regardless of the systolic BP changes during treatment. In both diabetic and nondiabetic patients, progressively greater systolic BP reductions were accompanied by reduced risk for the primary outcome only if baseline systolic BP levels ranged from 143 to 155 mm Hg; except for stroke, there was no benefit in fatal or nonfatal CV outcomes by reducing systolic BP below 130 mm Hg. CONCLUSIONS The relationship between BP and overall CV risk had a similar pattern in diabetic and nondiabetic patients over a wide range of baseline and in-treatment BP values although, for the same systolic BP, a higher risk is observed in diabetic patients.
Collapse
Affiliation(s)
- Josep Redon
- CIBERObn, Institute of Health Carlos III, Hospital Clínico Universitario, INCLIVA, Valencia, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
65
|
Cardiovascular medications and risk of cancer. Am J Cardiol 2011; 108:1045-51. [PMID: 21784384 DOI: 10.1016/j.amjcard.2011.05.041] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/15/2011] [Revised: 05/23/2011] [Accepted: 05/23/2011] [Indexed: 02/08/2023]
Abstract
Cardiovascular disease and cancer are 2 of the leading causes of death globally. Certain cardiovascular medications have been linked to an increased risk for cancer. Although individual reviews of specific classes of cardiovascular medications have been published previously, a more complete review of several classes has not been performed. The aim of this review is to evaluate the associations of various cardiovascular agents with the risk for developing cancer and provide guidance for clinicians. A comprehensive search of published research was conducted using MEDLINE from 1994 to 2011. Three trials demonstrated an increased risk for cancer using angiotensin II receptor blockers. Additionally, risk for cancer was shown in a number of trials that included the use of angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors. Five trials suggested that diuretics increased the risk for specific cancers, especially in women and those who had been using diuretics for >4 years. Statins and ezetimibe, in contrast, did not show this increased risk. Prasugrel was shown to be associated with an increased risk for cancer in 1 study. It appears that the use of certain cardiovascular medications is associated with an increased risk for cancer. In conclusion, clinicians need to balance the risks and benefits of the use of these agents and provide the appropriate therapy on an individual basis.
Collapse
|
66
|
Abstract
Hypertension occurs twice as commonly in diabetics than in comparable nondiabetics. Patients with both disorders have a markedly higher risk for premature microvascular and macrovascular complications. Aggressive control of blood pressure (BP) reduces both micro- and macrovascular complications. In diabetic hypertensives, angiotensin converting enzyme inhibitors (ACEIs) are the first line in management of hypertension, and can be replaced by angiotensin II receptor blockers (ARBs) if patients are intolerant of them. Recent studies suggest ARBs to be on par with ACEI in reducing both macro- and microvascular risks. Adding both these agents may have a beneficial effect on proteinuria, but no extra macrovascular risk reduction. Thiazides can also be used as first line drugs, but are better used along with ACEI/ARBs. Beta-blockers [especially if the patient has coronary artery disease] and calcium channel blockers are used as second line add-on drugs. Multidrug regimens are commonly needed in diabetic hypertensives. Achieving the target BP of <130/80 is the priority rather than the drug combination used in order to arrest and prevent the progression of macro- and microvascular complications in diabetic hypertensives.
Collapse
Affiliation(s)
- Jai Ganesh
- Department of Diabetology, M.V. Hospital for Diabetes, Prof. M. Viswanathan Diabetes Research Centre, WHO Collaborating Centre for Research, Education and Training in Diabetes, No.4, West Mada Church Street, Royapuram, Chennai, India
| | - Vijay Viswanathan
- Department of Diabetology, M.V. Hospital for Diabetes, Prof. M. Viswanathan Diabetes Research Centre, WHO Collaborating Centre for Research, Education and Training in Diabetes, No.4, West Mada Church Street, Royapuram, Chennai, India
| |
Collapse
|
67
|
Barzilay JI, Gao P, Rydén L, Schumacher H, Probstfield J, Commerford P, Dans A, Ferreira R, Keltai M, Paolasso E, Yusuf S, Teo K. Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study. Diabetes Care 2011; 34:1902-7. [PMID: 21788624 PMCID: PMC3161302 DOI: 10.2337/dc11-0545] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
OBJECTIVE Several large clinical trials suggest that ACE inhibitors may reduce the incidence of diabetes. Less is known about the effects of angiotensin receptor blockers (ARBs) on reducing incident diabetes or leading to regression of impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) to normoglycemia. RESEARCH DESIGN AND METHODS Participants were 3,488 adults at high risk for cardiovascular disease but free from diabetes (mean age 67 years; 61% male) in the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND) study. The participants were randomized to the ARB telmisartan 80 mg (n = 1,726) or placebo (n = 1,762) in addition to usual care. RESULTS During a median 56 months, 21.8% of participants treated with telmisartan and 22.4% of those on placebo developed diabetes (relative ratio 0.95 [95% CI 0.83-1.10]; P = 0.51). Participants originally diagnosed with IFG and/or IGT were equally likely to regress to normoglycemia (26.9 vs. 24.5%) or to progress to incident diabetes (20.1 vs. 21.1%; P = 0.59) on telmisartan or placebo. CONCLUSIONS There was no evidence that addition of the ARB telmisartan to usual care prevents incident diabetes or leads to regression of IFG or IGT in people at high risk for cardiovascular disease but free from diabetes.
Collapse
|
68
|
Suksomboon N, Poolsup N, Prasit T. Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes. J Clin Pharm Ther 2011; 37:319-27. [DOI: 10.1111/j.1365-2710.2011.01295.x] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
69
|
Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE). Adv Ther 2011; 28:698-706. [PMID: 21744143 DOI: 10.1007/s12325-011-0040-2] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2011] [Indexed: 01/13/2023]
Abstract
INTRODUCTION The number of patients with both hypertension and obesity has been increasing in Japan. Many of these patients may also have insulin resistance. Telmisartan, an angiotensin II receptor blocker (ARB), selectively activates peroxisome proliferatoractivated receptor (PPAR)-gamma, and this effect is considered to markedly improve insulin resistance in obese patients with hypertension. We compared the antihypertensive and insulin resistance-improving effects of telmisartan with those of candesartan and valsartan in this patient population. METHODS Twenty-eight elderly patients with an average body mass index (BMI) of 27.1 kg/m(2) were enrolled in this 6-month study. Patients were randomly selected to either switch from candesartan or valsartan to telmisartan or to continue with their current ARB. A 75 g oral glucose tolerance test (OGTT) was performed before and after switching, and the effect of telmisartan on the insulin response to glucose loading was investigated. RESULTS There was no significant difference in blood pressure between the two groups after drug administration, but glucose tolerance significantly improved in the telmisartan group. The hyperinsulin response to glucose loading also significantly improved in those taking telmisartan, as well as homeostasis model assessment of insulin resistance (HOMA-IR). These changes were not observed in the control group. CONCLUSION In patients with hypertension and obesity showing insulin resistance, treatment with telmisartan significantly improved the hyperinsulin response to glucose loading. Telmisartan may therefore be beneficial in these patients.
Collapse
|
70
|
Schmieder RE, Mann JFE, Schumacher H, Gao P, Mancia G, Weber MA, McQueen M, Koon T, Yusuf S. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 2011; 22:1353-64. [PMID: 21719791 DOI: 10.1681/asn.2010091001] [Citation(s) in RCA: 191] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
The degree of albuminuria predicts cardiovascular and renal outcomes, but it is not known whether changes in albuminuria also predict similar outcomes. In two multicenter, multinational, prospective observational studies, a central laboratory measured albuminuria in 23,480 patients with vascular disease or high-risk diabetes. We quantified the association between a greater than or equal to twofold change in albuminuria in spot urine from baseline to 2 years and the incidence of cardiovascular and renal outcomes and all-cause mortality during the subsequent 32 months. A greater than or equal to twofold increase in albuminuria from baseline to 2 years, observed in 28%, associated with nearly 50% higher mortality (HR 1.48; 95% CI 1.32 to 1.66), and a greater than or equal to twofold decrease in albuminuria, observed in 21%, associated with 15% lower mortality (HR 0.85; 95% CI 0.74 to 0.98) compared with those with lesser changes in albuminuria, after adjustment for baseline albuminuria, BP, and other potential confounders. Increases in albuminuria also significantly associated with cardiovascular death, composite cardiovascular outcomes (cardiovascular death, myocardial infarction, stroke, and hospitalization for heart failure), and renal outcomes including dialysis or doubling of serum creatinine (adjusted HR 1.40; 95% CI 1.11 to 1.78). In conclusion, in patients with vascular disease, changes in albuminuria predict mortality and cardiovascular and renal outcomes, independent of baseline albuminuria. This suggests that monitoring albuminuria is a useful strategy to help predict cardiovascular risk.
Collapse
Affiliation(s)
- Roland E Schmieder
- Department of Nephrology and Hypertension, University Hospital, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
71
|
Ram CVS. Reappraisal of role of angiotensin receptor blockers in cardiovascular protection. Vasc Health Risk Manag 2011; 7:315-9. [PMID: 21633521 PMCID: PMC3104608 DOI: 10.2147/vhrm.s15787] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2011] [Indexed: 01/13/2023] Open
Abstract
Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have shown cardioprotective and renoprotective properties. These agents are recommended as first-line therapy for the treatment of hypertension and the reduction of cardiovascular risk. Early studies pointed to the cardioprotective and renoprotective effects of ARBs in high-risk patients. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) established the clinical equivalence of the cardioprotective and renoprotective effects of telmisartan and ramipril, but did not find an added benefit of the combination over ramipril alone. Similar findings were observed in the Telmisartan Randomized AssessmeNt Study in aCE INtolerant subjects with cardiovascular Disease (TRANSCEND) trial conducted in ACEI-intolerant patients. In ONTARGET, telmisartan had a better tolerability profile with similar renoprotective properties compared with ramipril, suggesting a potential clinical benefit over ramipril. The recently completed Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial (ORIENT) and Olmesartan and Calcium Antagonists Randomized (OSCAR) studies will further define the role of ARBs in cardioprotection and renoprotection for high-risk patients.
Collapse
Affiliation(s)
- C Venkata S Ram
- Clinical Research Institute of Dallas Nephrology Associates, and Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75235, USA.
| |
Collapse
|
72
|
|
73
|
García-Donaire JA, Ruilope LM. Cardiovascular and Renal Links along the Cardiorenal Continuum. Int J Nephrol 2011; 2011:975782. [PMID: 21603119 PMCID: PMC3097083 DOI: 10.4061/2011/975782] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2010] [Accepted: 02/07/2011] [Indexed: 01/11/2023] Open
Abstract
The cardiorenal syndrome includes the widely known relationship between kidney function and cardiovascular disease. A large number of patients have various degrees of heart and kidney dysfunction worldwide, both in developed and developing countries. Disorders affecting one of them mostly involve the other. Such interactions represent the pathogenesis for a clinical condition called cardiorenal syndrome. Renal and cardiovascular disease shares similar etiologic risk factors. The majority of vascular events are caused by accelerated atherosclerosis. Moreover, cardiovascular events rarely occur in patients without underlying disease; rather, they typically take place as the final stage of a pathophysiological process that results in progressive vascular damage, including vital organ damage, specifically the kidney and the heart if these factors are uncontrolled. Chronic kidney disease is a novel risk factor included at this stage that accelerates both vascular and cardiac damage.
Collapse
|
74
|
Deppe S, Böger RH, Weiss J, Benndorf RA. Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties. Expert Opin Drug Metab Toxicol 2011; 6:863-71. [PMID: 20509777 DOI: 10.1517/17425255.2010.494597] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
IMPORTANCE OF THE FIELD Telmisartan belongs to the angiotensin II type 1 (AT1) receptor antagonizing class of antihypertensives, which are widely recognized and increasingly prescribed because of their good tolerability. Moreover, due to the results of the ONTARGET trial program, telmisartan was the first AT1 receptor antagonist to receive approval for the prevention of cardiovascular events in cardiovascular high risk patients, thereby, indicating that its clinical importance will further increase. AREAS COVERED IN THIS REVIEW This article reviews the pharmacokinetic and pharmacodynamic properties of telmisartan with a special focus on novel pharmacokinetic characteristics of the drug. WHAT THE READER WILL GAIN An overview of the published data regarding the pharmacokinetic properties of telmisartan as well as a summary of the results from selected small exploratory and large clinical outcome trials involving telmisartan. TAKE HOME MESSAGE Telmisartan is a safe and effective alternative for the treatment of hypertension. Moreover, due to its good tolerability, an increasing use of telmisartan in cardiovascular high risk patients can be anticipated. This will grant further experimental and clinical research on AT1 receptor-independent pharmacodynamics of telmisartan as well as on telmisartan-related drug safety issues.
Collapse
Affiliation(s)
- Sylvia Deppe
- Technical University of Braunschweig, Institute of Pharmacology, Toxicology, and Clinical Pharmacy, Mendelssohnstr. 1, D-38106 Braunschweig, Germany
| | | | | | | |
Collapse
|
75
|
Dans AL, Teo K, Gao P, Chen JH, Jae-Hyung K, Yusoff K, Chaithiraphan S, Zhu J, Lisheng L, Yusuf S. In a subgroup of high-risk Asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events. PLoS One 2010; 5:e13694. [PMID: 21200437 PMCID: PMC3006195 DOI: 10.1371/journal.pone.0013694] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2010] [Accepted: 09/21/2010] [Indexed: 01/13/2023] Open
Abstract
Background and Objectives Results of the recently published ONTARGET study (The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) showed that telmisartan (80 mg/day) was non-inferior to ramipril (10 mg/day) in reducing cardiovascular events. Clinicians in Asia doubt tolerability of these doses for their patients. We therefore analyzed data from this study and a parallel study TRANSCEND (Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease). Our objectives were to compare Asians and non-Asians with respect to the following: Method The ONTARGET study randomized 25,620 patients at risk of cardiovascular events to ramipril, telmisartan, or their combination. The primary composite endpoint was death caused by cardiovascular disease, acute MI, stroke, and hospitalization because of congestive heart failure. TRANSCEND randomized 5926 high-risk patients with a history of intolerance to ACE-inhibitors to telmisartan or placebo. The primary outcome was the same. In this substudy, we compared Asians and non-Asians as to how well they tolerated telmisartan (given in both studies) and ramipril (given in ONTARGET). Results 1) Telmisartan was non-inferior to ramipril in lowering the primary endpoint among Asians (RR = 0.92; 95% CI: 0.74, 1.13); 2) more Asians achieved the full dose of either drug; 3) less withdrew (overall); and 4) less withdrew for adverse effects. Furthermore, telmisartan was better tolerated than ramipril. This advantage was greater among Asians. Conclusion and Significance Although Asians had lower BMI than non-Asians, Asians tolerated both drugs better. Regulatory agencies require reporting of safety and effectiveness data by ethnicity, but few comply with this requirement. This study shows that safety data in ethnic subgroups can help assess applicability of results to specific populations. Trial Registration ClinicalTrials.gov NCT00153101
Collapse
Affiliation(s)
- Antonio L Dans
- University of the Philippines College of Medicine, Manila, Philippines.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
76
|
Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol 2010; 10:43-53. [PMID: 20980201 DOI: 10.1016/s1474-4422(10)70250-7] [Citation(s) in RCA: 138] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND cardiovascular risk factors are associated with dementia and cognitive decline. We investigated the effects of renin-angiotensin system blockade on cognitive function in patients aged 55 years and older with established atherosclerotic cardiovascular disease or diabetes with end-organ damage in two clinical trials. METHODS in the main study, ONTARGET, a double-blind, double-dummy, randomised controlled trial, the effects on cardiovascular outcomes of standard doses of an angiotensin-converting enzyme (ACE) inhibitor (ramipril), an angiotensin-receptor blocker (telmisartan), and a combination of the drugs were evaluated in 25 620 participants. In the parallel TRANSCEND trial, the effects of telmisartan were compared with those of placebo in 5926 participants intolerant to ACE inhibitors. Secondary outcomes included cognitive impairment (defined by investigator-reported diagnosis of dementia or significant cognitive dysfunction, or a score of ≤ 23 on the Mini-Mental State Examination [MMSE]) and cognitive decline (a decrease of ≤ 3 points on the MMSE from baseline during follow-up). Analyses were by intention to treat. We pooled data from these studies to identify baseline predictors of cognitive impairment and its frequency according to mean systolic blood pressure during follow-up. These studies were registered with ClinicalTrials.gov, number NCT00153101. FINDINGS During a median duration of 56 months (IQR 51-64) of follow-up in ONTARGET, cognitive impairment occurred in 652 (8%) of 7865 patients allocated ramipril, 584 (7%) of 7797 allocated telmisartan, and 618 (8%) of 7807 allocated combination treatment (combination vs ramipril, odds ratio [OR] 0·95, 95% CI 0·85-1·07, p= 0·39; telmisartan vs ramipril, OR 0·90, 0·80-1·01, p = 0·06). Corresponding figures for cognitive decline were 1314 (17%), 1279 (17%), and 1240 (17%) in each of the groups, respectively (telmisartan vs ramipril, OR 0·97, 0·89-1·06, p= 0·53; combination vs ramipril, OR 0·95, 0·88-1·04, p=0·28). In TRANSCEND, cognitive impairment occurred in 239 (9%) of 2694 participants allocated telmisartan compared with 245 (9%) of 2689 allocated placebo (OR 0·97, 0·81-1·17, p= 0·76). The corresponding figures for cognitive decline were 454 (17%) and 412 (16%; OR 1·10, 0·95-1·27, p= 0·22). INTERPRETATION In patients with cardiovascular disease or diabetes, different approaches to blocking of the renin-angiotensin system had no clear effects on cognitive outcomes. Although patients with the lowest systolic blood pressure had the greatest preservation of cognitive function, meta-regression analyses did not show any benefits of blood-pressure lowering on cognition over several years of treatment.
Collapse
|
77
|
Buzás GM. First-line eradication of Helicobacter pylori: Are the standard triple therapies obsolete? A different perspective. World J Gastroenterol 2010; 16:3865-70. [PMID: 20712046 PMCID: PMC2923759 DOI: 10.3748/wjg.v16.i31.3865] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Studies concerning the eradication of Helicobacter pylori have resulted in a proliferation of meta-analyses. To date, there are 303 meta-analyses cited in PubMed, 113 dealing with the therapy of the infection. A chronological analysis of the results of meta-analyses performed between 1998 and 2010 shows that first-line standard triple therapies achieved eradication rates on an intention-to-treat basis of around 80%; prolonging treatment to 14, but not 10 d should improve the results. The proton pump inhibitors have a similar efficiency, and giving a double dose is more efficient than the standard doses of these drugs. Triple and quadruple therapies proved to be equivalent. Based on meta-analytical data, the decrease in efficiency over time cannot be substantiated: eradication rates < 80% followed from the introduction of triple therapies. As alternatives, ranitidine bismuth citrate-, levofloxacin- or furazolidone-based therapies were shown to obtain the same eradication rates as standard triple regimens. Sequential therapies and quadruple non-bismuth-based therapies were superior to standard triple therapies but their use is limited to certain countries. In the author’s opinion, and from a meta-analytical viewpoint, standard triple therapies cannot yet be considered obsolete. Furthermore, non-inferiority trials are proposed for the future, including assessment of local contemporary antimicrobial resistance profiles and the CagA and CYP2C19 status of the enrolled patients.
Collapse
|
78
|
Saleem TSM, Bharani K, Gauthaman K. ACE inhibitors - angiotensin II receptor antagonists: A useful combination therapy for ischemic heart disease. Open Access Emerg Med 2010; 2:51-9. [PMID: 27147838 PMCID: PMC4806827 DOI: 10.2147/oaem.s10507] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Morbidity and mortality from cardiovascular diseases are still high, even with the use of the best available therapies. There is mounting evidence that excessive renin-angiotensin system activation triggers much of the damaging and progressive nature of cardiovascular and kidney diseases through expression of angiotensin II. Moreover, angiotensin II play a major role in the development of end organ damage through a variety of inflammatory mechanisms. Today, angiotensins-converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists have clearly demonstrated their efficacy in preventing target organ damage and in reducing cardiovascular morbidity and mortality in ischemic heart disease (IHD). Moreover, the development of angiotensin II receptor antagonists has enabled a large gain in tolerability and safety. Several clinical trials have firmly established that these drugs act on the renin–angiotensin system, reducing the incidence of coronary events with monotherapy and combination therapy. In this review we summarize the role mono- and combined therapy of ACE inhibitors and angiotensin II receptor antagonists play in ischemic heart disease. In this respect the review will improve ideas for developing new formulations with combinations of these drugs in the future.
Collapse
Affiliation(s)
- T S Mohamed Saleem
- Department of Pharmacology, Annamacharya College of Pharmacy, Rajampet-516126, Kadapa Dist, Andhra Pradesh, India
| | - K Bharani
- Department of Pharmacology, Annamacharya College of Pharmacy, Rajampet-516126, Kadapa Dist, Andhra Pradesh, India
| | - K Gauthaman
- Department of Drug Technology, Higher Institute of Medical Technology, Derna, Libya
| |
Collapse
|
79
|
Telmisartan suppresses cerebral injury in a murine model of transient focal ischemia. Brain Res 2010; 1340:70-80. [DOI: 10.1016/j.brainres.2010.03.101] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2009] [Revised: 03/27/2010] [Accepted: 03/31/2010] [Indexed: 01/04/2023]
|
80
|
The combination of amlodipine and angiotensin receptor blocker or diuretics in high-risk hypertensive patients: rationale, design and baseline characteristics. J Hum Hypertens 2010; 25:271-7. [PMID: 20445570 PMCID: PMC3061000 DOI: 10.1038/jhh.2010.45] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The Chinese Hypertension Intervention Efficacy Study (CHIEF) is a multi-centre randomized controlled clinical trial comparing the effects of amlodipine+angiotensin II receptor blocker and amlodipine+diuretics on the incidence of cardiovascular events, represented as a composite of non-fatal stroke, non-fatal myocardial infarction and cardiovascular death events in high-risk Chinese hypertensive patients. The study also evaluates the long-term effects of lipid-lowering treatment and lifestyle modification. From October 2007 to October 2008, 13 542 patients were enrolled into the study in 180 centres in China. Patients will be followed up for 4 years. There was no difference in baseline characteristics between the two blood pressure arms.
Collapse
|
81
|
Böhm M, Baumhäkel M, Teo K, Sleight P, Probstfield J, Gao P, Mann JF, Diaz R, Dagenais GR, Jennings GL, Liu L, Jansky P, Yusuf S. Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both. Circulation 2010; 121:1439-46. [DOI: 10.1161/circulationaha.109.864199] [Citation(s) in RCA: 145] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background—
Although erectile dysfunction (ED) is associated with cardiovascular risk factors and atherosclerosis, it is not known whether the presence of ED is predictive of future events in individuals with cardiovascular disease. We evaluated whether ED is predictive of mortality and cardiovascular outcomes, and because inhibition of the renin-angiotensin system in high-risk patients reduces cardiovascular events, we also tested the effects on ED of randomized treatments with telmisartan, ramipril, and the combination of the 2 drugs (ONTARGET), as well as with telmisartan or placebo in patients who were intolerant of angiotensin-converting enzyme inhibitors (TRANSCEND).
Methods and Results—
In a prespecified substudy, 1549 patients underwent double-blind randomization, with 400 participants assigned to receive ramipril, 395 telmisartan, and 381 the combination thereof (ONTARGET), as well as 171 participants assigned to receive telmisartan and 202 placebo (TRANSCEND). ED was evaluated at baseline, at 2-year follow-up, and at the penultimate visit before closeout. ED was predictive of all-cause death (hazard ratio [HR] 1.84, 95% confidence interval [CI] 1.21 to 2.81,
P
=0.005) and the composite primary outcome (HR 1.42, 95% CI 1.04 to 1.94,
P
=0.029), which consisted of cardiovascular death (HR 1.93, 95% CI 1.13 to 3.29,
P
=0.016), myocardial infarction (HR 2.02, 95% CI 1.13 to 3.58,
P
=0.017), hospitalization for heart failure (HR 1.2, 95% CI 0.64 to 2.26,
P
=0.563), and stroke (HR 1.1, 95% CI 0.64 to 1.9,
P
=0.742). The study medications did not influence the course or development of ED.
Conclusions—
ED is a potent predictor of all-cause death and the composite of cardiovascular death, myocardial infarction, stroke, and heart failure in men with cardiovascular disease. Trial treatment did not significantly improve or worsen ED.
Clinical Trial Registration—
URL: http://www.clinicaltrials.gov. Unique identifier: NCT 00153101.
Collapse
Affiliation(s)
- Michael Böhm
- From the Department of Cardiology, University of the Saarland (M. Böhm, M. Baumhäkel), Saarbrücken, Germany; Population Health Research Institute (KT, P.G., S.Y.), McMaster University/Hamilton Health Sciences, Hamilton, Ontario, Canada; University of Oxford (P.S.), Oxford, United Kingdom; University of Washington, School of Medicine (J.P.), Seattle, Wash; Department of Nephrology, Hypertension and Rheumatology, Schwabing General Hospital (J.F.M.), Munich, Germany; Department of Cardiology,
| | - Magnus Baumhäkel
- From the Department of Cardiology, University of the Saarland (M. Böhm, M. Baumhäkel), Saarbrücken, Germany; Population Health Research Institute (KT, P.G., S.Y.), McMaster University/Hamilton Health Sciences, Hamilton, Ontario, Canada; University of Oxford (P.S.), Oxford, United Kingdom; University of Washington, School of Medicine (J.P.), Seattle, Wash; Department of Nephrology, Hypertension and Rheumatology, Schwabing General Hospital (J.F.M.), Munich, Germany; Department of Cardiology,
| | - Koon Teo
- From the Department of Cardiology, University of the Saarland (M. Böhm, M. Baumhäkel), Saarbrücken, Germany; Population Health Research Institute (KT, P.G., S.Y.), McMaster University/Hamilton Health Sciences, Hamilton, Ontario, Canada; University of Oxford (P.S.), Oxford, United Kingdom; University of Washington, School of Medicine (J.P.), Seattle, Wash; Department of Nephrology, Hypertension and Rheumatology, Schwabing General Hospital (J.F.M.), Munich, Germany; Department of Cardiology,
| | - Peter Sleight
- From the Department of Cardiology, University of the Saarland (M. Böhm, M. Baumhäkel), Saarbrücken, Germany; Population Health Research Institute (KT, P.G., S.Y.), McMaster University/Hamilton Health Sciences, Hamilton, Ontario, Canada; University of Oxford (P.S.), Oxford, United Kingdom; University of Washington, School of Medicine (J.P.), Seattle, Wash; Department of Nephrology, Hypertension and Rheumatology, Schwabing General Hospital (J.F.M.), Munich, Germany; Department of Cardiology,
| | - Jeffrey Probstfield
- From the Department of Cardiology, University of the Saarland (M. Böhm, M. Baumhäkel), Saarbrücken, Germany; Population Health Research Institute (KT, P.G., S.Y.), McMaster University/Hamilton Health Sciences, Hamilton, Ontario, Canada; University of Oxford (P.S.), Oxford, United Kingdom; University of Washington, School of Medicine (J.P.), Seattle, Wash; Department of Nephrology, Hypertension and Rheumatology, Schwabing General Hospital (J.F.M.), Munich, Germany; Department of Cardiology,
| | - Peggy Gao
- From the Department of Cardiology, University of the Saarland (M. Böhm, M. Baumhäkel), Saarbrücken, Germany; Population Health Research Institute (KT, P.G., S.Y.), McMaster University/Hamilton Health Sciences, Hamilton, Ontario, Canada; University of Oxford (P.S.), Oxford, United Kingdom; University of Washington, School of Medicine (J.P.), Seattle, Wash; Department of Nephrology, Hypertension and Rheumatology, Schwabing General Hospital (J.F.M.), Munich, Germany; Department of Cardiology,
| | - Johannes F. Mann
- From the Department of Cardiology, University of the Saarland (M. Böhm, M. Baumhäkel), Saarbrücken, Germany; Population Health Research Institute (KT, P.G., S.Y.), McMaster University/Hamilton Health Sciences, Hamilton, Ontario, Canada; University of Oxford (P.S.), Oxford, United Kingdom; University of Washington, School of Medicine (J.P.), Seattle, Wash; Department of Nephrology, Hypertension and Rheumatology, Schwabing General Hospital (J.F.M.), Munich, Germany; Department of Cardiology,
| | - Rafael Diaz
- From the Department of Cardiology, University of the Saarland (M. Böhm, M. Baumhäkel), Saarbrücken, Germany; Population Health Research Institute (KT, P.G., S.Y.), McMaster University/Hamilton Health Sciences, Hamilton, Ontario, Canada; University of Oxford (P.S.), Oxford, United Kingdom; University of Washington, School of Medicine (J.P.), Seattle, Wash; Department of Nephrology, Hypertension and Rheumatology, Schwabing General Hospital (J.F.M.), Munich, Germany; Department of Cardiology,
| | - Gilles R. Dagenais
- From the Department of Cardiology, University of the Saarland (M. Böhm, M. Baumhäkel), Saarbrücken, Germany; Population Health Research Institute (KT, P.G., S.Y.), McMaster University/Hamilton Health Sciences, Hamilton, Ontario, Canada; University of Oxford (P.S.), Oxford, United Kingdom; University of Washington, School of Medicine (J.P.), Seattle, Wash; Department of Nephrology, Hypertension and Rheumatology, Schwabing General Hospital (J.F.M.), Munich, Germany; Department of Cardiology,
| | - Garry L.R. Jennings
- From the Department of Cardiology, University of the Saarland (M. Böhm, M. Baumhäkel), Saarbrücken, Germany; Population Health Research Institute (KT, P.G., S.Y.), McMaster University/Hamilton Health Sciences, Hamilton, Ontario, Canada; University of Oxford (P.S.), Oxford, United Kingdom; University of Washington, School of Medicine (J.P.), Seattle, Wash; Department of Nephrology, Hypertension and Rheumatology, Schwabing General Hospital (J.F.M.), Munich, Germany; Department of Cardiology,
| | - Lisheng Liu
- From the Department of Cardiology, University of the Saarland (M. Böhm, M. Baumhäkel), Saarbrücken, Germany; Population Health Research Institute (KT, P.G., S.Y.), McMaster University/Hamilton Health Sciences, Hamilton, Ontario, Canada; University of Oxford (P.S.), Oxford, United Kingdom; University of Washington, School of Medicine (J.P.), Seattle, Wash; Department of Nephrology, Hypertension and Rheumatology, Schwabing General Hospital (J.F.M.), Munich, Germany; Department of Cardiology,
| | - Petr Jansky
- From the Department of Cardiology, University of the Saarland (M. Böhm, M. Baumhäkel), Saarbrücken, Germany; Population Health Research Institute (KT, P.G., S.Y.), McMaster University/Hamilton Health Sciences, Hamilton, Ontario, Canada; University of Oxford (P.S.), Oxford, United Kingdom; University of Washington, School of Medicine (J.P.), Seattle, Wash; Department of Nephrology, Hypertension and Rheumatology, Schwabing General Hospital (J.F.M.), Munich, Germany; Department of Cardiology,
| | - Salim Yusuf
- From the Department of Cardiology, University of the Saarland (M. Böhm, M. Baumhäkel), Saarbrücken, Germany; Population Health Research Institute (KT, P.G., S.Y.), McMaster University/Hamilton Health Sciences, Hamilton, Ontario, Canada; University of Oxford (P.S.), Oxford, United Kingdom; University of Washington, School of Medicine (J.P.), Seattle, Wash; Department of Nephrology, Hypertension and Rheumatology, Schwabing General Hospital (J.F.M.), Munich, Germany; Department of Cardiology,
| |
Collapse
|
82
|
Staessen JA, Richart T, Wang Z, Thijs L. Implications of recently published trials of blood pressure-lowering drugs in hypertensive or high-risk patients. Hypertension 2010; 55:819-31. [PMID: 20212274 DOI: 10.1161/hypertensionaha.108.122879] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
We reviewed 6 recent outcome trials of blood pressure (BP)-lowering drugs in 74,524 randomized hypertensive or high-risk patients. Over interpretation of nonsignificant or marginal probability values in large trials with overlapping end points, exclusion of patients not tolerating or not adhering to experimental treatments, labeling nonsignificant treatment effects as modest, and insufficient information on the quality of the BP measurements or on the BP changes early after randomization raise concern. From a clinical viewpoint, results should not be extrapolated to patients with characteristics dissimilar from those randomized. The benefit beyond BP lowering in cardiovascular prevention is tiny. Dual inhibition of the renin system should only be used in patients at high risk, in whom all drug combinations have been tried and who cannot be controlled by a single renin system inhibitor. Current evidence does not support BP lowering in normotensive patients or the use of renin system inhibitors for prevention of stroke recurrence. Because angiotensin-receptor blockers might offer less protection against myocardial infarction than angiotensin-converting enzyme inhibitors, the latter should remain the preferred renin system inhibitor for cardiovascular prevention in angiotensin-converting enzyme inhibitor-tolerant patients. In 2 trials, in which new-onset diabetes was a predefined end point, 1000 patients had to be treated for 1 year with an angiotensin-receptor blocker instead of placebo to prevent just 2 cases. From a design viewpoint, the time has come to revise the concept of large simple trials and to pursue research questions that serve patient interests more than showing noninferiority or highlight the ancillary qualities of marketable antihypertensive drugs.
Collapse
Affiliation(s)
- Jan A Staessen
- Studies Coordinating Centre, Division of Hypertension and Cardiovascular Rehabilitation, Department of Cardiovascular Diseases, University of Leuven, Campus Sint Rafaël, Kapucijnenvoer 35, Block d, Level 00, Box 7001, B-3000 Leuven, Belgium.
| | | | | | | |
Collapse
|
83
|
Van Mieghem W, Billiouw JM, Brohet C, Dupont AG, Gazagnes MD, Heller F, Krzesinski JM, Missault L, Persu A, Piérard L, Rottiers R, Vanhooren G, Vervaet P, Herman AG. Are ACE-inhibitors or ARB's still needed for cardiovascular prevention in high risk patients? Insights from profess and transcend. Acta Clin Belg 2010; 65:107-14. [PMID: 20491360 DOI: 10.1179/acb.2010.022] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The HOPE and EUROPA clinical studies have shown that treatment with the angiotensin-converting enzyme (ACE) inhibitors, ramipril and perindopril, may reduce the occurrence of major cardiovascular events in patients with proven atherosclerotic disease. The recently published results of the PRoFESS and TRANSCEND trials completed the much needed information concerning the use of an angiotensin receptor blocker for patients at high risk of cardiovascular events. PROFESS compared a therapy of telmisartan 80 mg daily with placebo in patients with a recent ischemic stroke. The difference in the primary outcome of first recurrent stroke was not statistically significant between telmisartan and placebo. The secondary outcome of major cardiovascular events showed a relative risk reduction (RRR) of 7% in favour of telmisartan. This tended to be significant (p = 0.06) despite a rather short follow-up period of only 28 months. In TRANSCEND 5926 patients at high risk for cardiovascular events were randomized to a treatment with telmisartan 80 mg daily or placebo for a mean duration of follow-up of 56 months. The primary composite outcome of cardiovascular death, myocardial infarction, stroke or hospitalization for heart failure showed a non-significant 8% RRR in favour of the telmisartan treated patients. The main secondary outcome of cardiovascular death and myocardial infarction or stroke as used in the HOPE trial showed a non-significant RRR of 13% in favour of telmisartan treated patients (p = 0.068 adjusted for multiplicity of comparisons). In comparing the Kaplan-Meier curves for the endpoint of major cardiovascular events used in HOPE, EUROPA, TRANSCEND and PRoFESS, the trends are similar. Results of most of the recently published trials have been neutral.This could partly be explained by major improvements in the optimal background therapy of the patients included. Nevertheless, the results of PRoFESS and TRANSCEND do not contradict the results from previous studies with theACE inhibitors ramipril and perindopril and the ARB telmisartan.
Collapse
Affiliation(s)
- W Van Mieghem
- Ziekenhuis Oost-Limburg, Genk Department of Cardiology Oude Postbaan, 60 B-3600 Genk.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
84
|
Acikel S, Akdemir R, Kilic H, Yesilay AB, Dogan M, Cagirci G. Diastolic heart failure in elderly: The prognostic factors and interventions regarding heart failure with preserved ejection fraction. Int J Cardiol 2010; 138:311-3. [DOI: 10.1016/j.ijcard.2008.06.068] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/09/2008] [Accepted: 06/28/2008] [Indexed: 10/21/2022]
|
85
|
Abstract
Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) are recognized to reduce cardiovascular and renal morbidity and mortality, which is primarily attributed to their antihypertensive effects. Activation of the renin-angiotensin system (RAS) may also play an important role in the pathogenesis of cardiovascular and renal disease through blood pressure-independent mechanisms mediated by angiotensin II. Thus, inhibiting the RAS with either an ARB or an ACE inhibitor may confer additional benefit in people with advanced nephropathy that cannot be explained totally by reductions in blood pressure. Preclinical evidence suggests that blood pressure lowering is not solely responsible for the organ and tissue protective effects of ACE inhibitors or ARBs. Furthermore, clinical studies evaluating effects on end organs and surrogate markers have shown that these agents have blood pressure-independent effects. There is also intriguing evidence that agents in the same class may differ in their effects on renal function despite similar blood pressure control. Support for blood pressure-independent effects comes from outcome studies. Agents evaluated in such studies and that appear to have effects independent of blood pressure lowering include irbesartan, losartan, ramipril, and telmisartan. Taken together, this body of evidence indicates that the clinical benefits of ARBs and ACE inhibitors in patients with advanced nephropathy extend beyond blood pressure reduction. Therefore, although antihypertensive efficacy is of primary importance in choosing a treatment to provide cardiovascular and renal protection, consideration should be given to the effects of an agent that extend beyond blood pressure.
Collapse
|
86
|
|
87
|
Cowan BR, Young AA, Anderson C, Doughty RN, Krittayaphong R, Lonn E, Marwick TH, Reid CM, Sanderson JE, Schmieder RE, Teo K, Wadham AK, Worthley SG, Yu CM, Yusuf S, Jennings GL. Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]). Am J Cardiol 2009; 104:1484-9. [PMID: 19932779 DOI: 10.1016/j.amjcard.2009.07.018] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/06/2009] [Revised: 07/10/2009] [Accepted: 07/10/2009] [Indexed: 01/20/2023]
Abstract
The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) showed that the angiotensin receptor blocker telmisartan 80 mg was not inferior to the angiotensin-converting enzyme inhibitor ramipril 10 mg, and the combination no more effective than ramipril alone, in decreasing morbidity and mortality in patients with cardiovascular disease or high-risk diabetes. Although therapy targeting angiotensin II is known to decrease left ventricular (LV) mass and volume, the relative influence of angiotensin-converting enzyme inhibitor inhibitors and angiotensin receptor blocker, and their combination, on the heart remains unclear in this population. Magnetic resonance imaging was performed in 287 patients enrolled in ONTARGET, across 8 centers in 6 countries, at randomization and after 2-year treatment (90, 100, and 97 patients in the ramipril, telmisartan, and combination therapy groups, respectively). Baseline patient characteristics showed higher frequencies of coronary artery disease, Asian ethnicity, and use of statins and beta blockers than the main ONTARGET trial. LV mass decreased in all groups (p <0.0001 for each), but there were no significant differences in change in LV mass or volume among groups, except that LV mass index decreased more on combination versus telmisartan (p = 0.04). Key determinants of LV mass decrease were a history of hypertension (p = 0.03), baseline mass (p <0.0001), and decrease in systolic blood pressure (p <0.0001). The best magnetic resonance imaging predictor of composite events was end-systolic volume (p <0.0001). In conclusion, telmisartan and ramipril had similar effects on LV mass and volume, and combination therapy was not more effective, in high-risk patients with cardiovascular disease. These results are consistent with the major outcome findings of the main ONTARGET study.
Collapse
|
88
|
Baumhäkel M, Böhm M. Telmisartan prevents cardiovascular events in a broad group of at-risk patients. Expert Opin Pharmacother 2009; 10:3113-7. [PMID: 19925045 DOI: 10.1517/14656560903449231] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) was a 25,620 patient study program comparing telmisartan with ramipril or the combination thereof in patients at increased cardiovascular risk. Ramipril had previously been proven to prevent cardiovascular events in a similar population within the HOPE-trial. However, ramipril and other ACE inhibitors (ACE-Is) may have limited tolerability that might restrict their use in patients requiring secondary prevention, whereas angiotensin receptor blockers (ARBs) are suggested to be better tolerated. However, no ARB had been compared with the standard treatment, ramipril, in these cardiovascular patients at increased risk. ONTARGET showed that telmisartan was as effective as ramipril in preventing cardiovascular events, but was better tolerated. The combination of ramipril and telmisartan was not superior to either monotherapy. Taken together, ONTARGET demonstrated that telmisartan is as effective as ramipril in a broad cardiovascular increased-risk population in the middle of the cardiovascular continuum. In these patients who are intolerant to ACE-Is or who do not achieve blood pressure control, the ARB with the best evidence for secondary prevention is telmisartan according to the results of the ONTARGET trial.
Collapse
Affiliation(s)
- Magnus Baumhäkel
- University Hospital of the Saarland, Department of Cardiology, Homburg Saar, Germany.
| | | |
Collapse
|
89
|
Bohm M, Mahfoud F, Werner C, Teo K, Baumhakel M. Cardiovascular protection: a breakthrough for high-risk patients. Eur Heart J Suppl 2009. [DOI: 10.1093/eurheartj/sup024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
90
|
|
91
|
Dobre D, Lambers Heerspink HJ, de Zeeuw D. Reducing cardiovascular risk: protecting the kidney. Eur Heart J Suppl 2009. [DOI: 10.1093/eurheartj/sup027] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
92
|
|
93
|
Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor. J Hypertens 2009; 27:S23-9. [PMID: 19587551 DOI: 10.1097/01.hjh.0000357905.78704.9a] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The Heart Outcomes Prevention Evaluation study established the angiotensin-converting enzyme inhibitor ramipril, versus placebo, for prevention of cardiovascular events in high-risk patients. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) was later conducted in similar high-risk patients using multifactorial treatment to control hypertension, platelet aggregation, and dyslipidemia, while comparing ramipril, telmisartan, or their combination, without placebo. In ONTARGET, the first angiotensin II receptor blocker-based study to be performed in a broader population of patients without congestive heart failure and/or left ventricular hypertrophy/dysfunction, telmisartan provided cardiovascular protection that was noninferior to ramipril. However, greater blockade of the renin-angiotensin system, using their combination, was not superior to ramipril alone. Telmisartan was better tolerated than ramipril in this high-risk population: notably, the incidence of cough and angioedema was significantly lower with telmisartan alone. Thus, telmisartan provides comparable efficacy to ramipril with less adverse events, which may encourage patient compliance.
Collapse
|
94
|
Abstract
BACKGROUND Peripheral arterial disease (PAD) causes considerable morbidity and mortality. Hypertension is a risk factor for PAD. Treatment for hypertension must be compatible with the symptoms of PAD. Controversy regarding the effects of beta-blockade for hypertension in patients with PAD has led many physicians to stop prescribing beta-blockers. Little is known about the effects of other classes of anti-hypertensive drugs in the presence of PAD. This is an update of a Cochrane review first published in 2003. OBJECTIVES To determine the effects of anti-hypertensive drugs on cardiovascular events and death, symptoms of claudication, critical leg ischaemia, progression of PAD and revascularisation or amputation in people with hypertension and PAD SEARCH STRATEGY: The Cochrane Peripheral Vascular Diseases Group searched their Specialised Register (last searched May 2009) and the Cochrane Central Register of Controlled Trials (The Cochrane Library 2009, Issue 2). The authors studied abstracts of cardiology meetings. SELECTION CRITERIA Randomised controlled trials of at least one anti-hypertensive treatment against placebo, or two anti-hypertensive medications against each other, with interventions lasting at least one month. Trials had to include patients with symptomatic PAD. DATA COLLECTION AND ANALYSIS Data were extracted by one author (DAL) and checked by the other (GYHL). Eligible studies were excluded when results presentation prevented adequate extraction of data and enquiries to authors did not yield raw data. MAIN RESULTS Four studies were included. Two compared ACE inhibitors against placebo. In the HOPE study there was a significant reduction in the number of cardiovascular events in 168 patients receiving ramipril (OR 0.72, 95% confidence interval 0.58 to 0.91). In the second trial using perindopril in a small numbers of patients, there was a marginal increase in claudication distance but no change in ankle brachial pressure index (ABPI) and a reduction in maximum walking distance.The third trial in patients undergoing angioplasty suggested that the calcium antagonist verapamil reduced restenosis, although this was not reflected in the maintenance of a high ABPI. Another small study demonstrated no significant difference in arterial intima-media thickness with men receiving the thiazide diuretic hydrochlorathiazide compared to those receiving the alpha-adrenoreceptor blocker doxazosin. AUTHORS' CONCLUSIONS Evidence on various anti-hypertensive drugs in people with PAD is poor so that it is unknown whether significant benefits or risks accrue from their use. Lack of data specifically examining outcomes in PAD patients should not detract from the compelling evidence of the benefit of treating hypertension and lowering blood pressure.
Collapse
Affiliation(s)
- Deirdre A Lane
- Haemostasis Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Dudley Road, Birmingham, UK, B18 7QH
| | | |
Collapse
|
95
|
Verdecchia P, Sleight P, Mancia G, Fagard R, Trimarco B, Schmieder RE, Kim JH, Jennings G, Jansky P, Chen JH, Liu L, Gao P, Probstfield J, Teo K, Yusuf S. Effects of Telmisartan, Ramipril, and Their Combination on Left Ventricular Hypertrophy in Individuals at High Vascular Risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. Circulation 2009; 120:1380-9. [DOI: 10.1161/circulationaha.109.865774] [Citation(s) in RCA: 90] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background—
Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers reduce left ventricular hypertrophy (LVH). The effect of these drugs on LVH in high-risk patients without heart failure is unknown.
Methods and Results—
In the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET), patients at high vascular risk and tolerant of ACE inhibitors were randomly assigned to ramipril, telmisartan, or their combination (n=23 165). In the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND), patients intolerant of ACE inhibitors were randomized to telmisartan or placebo (n=5343). Prevalence of LVH at entry in TRANSCEND was 12.7%. It was reduced by telmisartan (10.5% and 9.9% after 2 and 5 years) compared with placebo (12.7% and 12.8% after 2 and 5 years) (overall odds ratio, 0.79; 95% confidence interval [CI], 0.68 to 0.91;
P
=0.0017). New-onset LVH occurred less frequently with telmisartan compared with placebo (overall odds ratio, 0.63; 95% CI, 0.51 to 0.79;
P
=0.0001). LVH regression was similar in the 2 groups. In ONTARGET, prevalence of LVH at entry was 12.4%. At follow-up, it occurred slightly less frequently with telmisartan (odds ratio, 0.92; 95% CI, 0.83 to 1.01;
P
=0.07) and the combination (odds ratio, 0.93; 95% CI, 0.84 to 1.02;
P
=0.12) than with ramipril, but differences between the groups were not significant. New-onset LVH was associated with a higher risk of primary outcome during follow-up (hazard ratio, 1.77; 95% CI, 1.50 to 2.07).
Conclusions—
In patients at high vascular risk, telmisartan is more effective than placebo in reducing LVH. New-onset LVH is reduced by 37%. The effect of combination of the 2 drugs on LVH is similar to that of ramipril alone.
Collapse
Affiliation(s)
- Paolo Verdecchia
- From the Hospital S. Maria della Misericordia, Clinical Research Unit Preventive Cardiology, Perugia, Italy (P.V.); Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada (P.V., P.G., K.T., S.Y.); Cardiovascular Medicine, John Radcliffe Hospital, Oxford, UK (P.S.); University of Milano-Bicocca, Milano, Italy (G.M.); Hypertension Unit, Catholic University of Leuven, Leuven, Belgium (R.F.); Department of Clinical Medicine and Cardiovascular and Immunological Sciences,
| | - Peter Sleight
- From the Hospital S. Maria della Misericordia, Clinical Research Unit Preventive Cardiology, Perugia, Italy (P.V.); Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada (P.V., P.G., K.T., S.Y.); Cardiovascular Medicine, John Radcliffe Hospital, Oxford, UK (P.S.); University of Milano-Bicocca, Milano, Italy (G.M.); Hypertension Unit, Catholic University of Leuven, Leuven, Belgium (R.F.); Department of Clinical Medicine and Cardiovascular and Immunological Sciences,
| | - Giuseppe Mancia
- From the Hospital S. Maria della Misericordia, Clinical Research Unit Preventive Cardiology, Perugia, Italy (P.V.); Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada (P.V., P.G., K.T., S.Y.); Cardiovascular Medicine, John Radcliffe Hospital, Oxford, UK (P.S.); University of Milano-Bicocca, Milano, Italy (G.M.); Hypertension Unit, Catholic University of Leuven, Leuven, Belgium (R.F.); Department of Clinical Medicine and Cardiovascular and Immunological Sciences,
| | - Robert Fagard
- From the Hospital S. Maria della Misericordia, Clinical Research Unit Preventive Cardiology, Perugia, Italy (P.V.); Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada (P.V., P.G., K.T., S.Y.); Cardiovascular Medicine, John Radcliffe Hospital, Oxford, UK (P.S.); University of Milano-Bicocca, Milano, Italy (G.M.); Hypertension Unit, Catholic University of Leuven, Leuven, Belgium (R.F.); Department of Clinical Medicine and Cardiovascular and Immunological Sciences,
| | - Bruno Trimarco
- From the Hospital S. Maria della Misericordia, Clinical Research Unit Preventive Cardiology, Perugia, Italy (P.V.); Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada (P.V., P.G., K.T., S.Y.); Cardiovascular Medicine, John Radcliffe Hospital, Oxford, UK (P.S.); University of Milano-Bicocca, Milano, Italy (G.M.); Hypertension Unit, Catholic University of Leuven, Leuven, Belgium (R.F.); Department of Clinical Medicine and Cardiovascular and Immunological Sciences,
| | - Roland E. Schmieder
- From the Hospital S. Maria della Misericordia, Clinical Research Unit Preventive Cardiology, Perugia, Italy (P.V.); Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada (P.V., P.G., K.T., S.Y.); Cardiovascular Medicine, John Radcliffe Hospital, Oxford, UK (P.S.); University of Milano-Bicocca, Milano, Italy (G.M.); Hypertension Unit, Catholic University of Leuven, Leuven, Belgium (R.F.); Department of Clinical Medicine and Cardiovascular and Immunological Sciences,
| | - Jae-Hyung Kim
- From the Hospital S. Maria della Misericordia, Clinical Research Unit Preventive Cardiology, Perugia, Italy (P.V.); Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada (P.V., P.G., K.T., S.Y.); Cardiovascular Medicine, John Radcliffe Hospital, Oxford, UK (P.S.); University of Milano-Bicocca, Milano, Italy (G.M.); Hypertension Unit, Catholic University of Leuven, Leuven, Belgium (R.F.); Department of Clinical Medicine and Cardiovascular and Immunological Sciences,
| | - Garry Jennings
- From the Hospital S. Maria della Misericordia, Clinical Research Unit Preventive Cardiology, Perugia, Italy (P.V.); Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada (P.V., P.G., K.T., S.Y.); Cardiovascular Medicine, John Radcliffe Hospital, Oxford, UK (P.S.); University of Milano-Bicocca, Milano, Italy (G.M.); Hypertension Unit, Catholic University of Leuven, Leuven, Belgium (R.F.); Department of Clinical Medicine and Cardiovascular and Immunological Sciences,
| | - Petr Jansky
- From the Hospital S. Maria della Misericordia, Clinical Research Unit Preventive Cardiology, Perugia, Italy (P.V.); Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada (P.V., P.G., K.T., S.Y.); Cardiovascular Medicine, John Radcliffe Hospital, Oxford, UK (P.S.); University of Milano-Bicocca, Milano, Italy (G.M.); Hypertension Unit, Catholic University of Leuven, Leuven, Belgium (R.F.); Department of Clinical Medicine and Cardiovascular and Immunological Sciences,
| | - Jyh-Hong Chen
- From the Hospital S. Maria della Misericordia, Clinical Research Unit Preventive Cardiology, Perugia, Italy (P.V.); Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada (P.V., P.G., K.T., S.Y.); Cardiovascular Medicine, John Radcliffe Hospital, Oxford, UK (P.S.); University of Milano-Bicocca, Milano, Italy (G.M.); Hypertension Unit, Catholic University of Leuven, Leuven, Belgium (R.F.); Department of Clinical Medicine and Cardiovascular and Immunological Sciences,
| | - Lisheng Liu
- From the Hospital S. Maria della Misericordia, Clinical Research Unit Preventive Cardiology, Perugia, Italy (P.V.); Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada (P.V., P.G., K.T., S.Y.); Cardiovascular Medicine, John Radcliffe Hospital, Oxford, UK (P.S.); University of Milano-Bicocca, Milano, Italy (G.M.); Hypertension Unit, Catholic University of Leuven, Leuven, Belgium (R.F.); Department of Clinical Medicine and Cardiovascular and Immunological Sciences,
| | - Peggy Gao
- From the Hospital S. Maria della Misericordia, Clinical Research Unit Preventive Cardiology, Perugia, Italy (P.V.); Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada (P.V., P.G., K.T., S.Y.); Cardiovascular Medicine, John Radcliffe Hospital, Oxford, UK (P.S.); University of Milano-Bicocca, Milano, Italy (G.M.); Hypertension Unit, Catholic University of Leuven, Leuven, Belgium (R.F.); Department of Clinical Medicine and Cardiovascular and Immunological Sciences,
| | - Jeffrey Probstfield
- From the Hospital S. Maria della Misericordia, Clinical Research Unit Preventive Cardiology, Perugia, Italy (P.V.); Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada (P.V., P.G., K.T., S.Y.); Cardiovascular Medicine, John Radcliffe Hospital, Oxford, UK (P.S.); University of Milano-Bicocca, Milano, Italy (G.M.); Hypertension Unit, Catholic University of Leuven, Leuven, Belgium (R.F.); Department of Clinical Medicine and Cardiovascular and Immunological Sciences,
| | - Koon Teo
- From the Hospital S. Maria della Misericordia, Clinical Research Unit Preventive Cardiology, Perugia, Italy (P.V.); Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada (P.V., P.G., K.T., S.Y.); Cardiovascular Medicine, John Radcliffe Hospital, Oxford, UK (P.S.); University of Milano-Bicocca, Milano, Italy (G.M.); Hypertension Unit, Catholic University of Leuven, Leuven, Belgium (R.F.); Department of Clinical Medicine and Cardiovascular and Immunological Sciences,
| | - Salim Yusuf
- From the Hospital S. Maria della Misericordia, Clinical Research Unit Preventive Cardiology, Perugia, Italy (P.V.); Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada (P.V., P.G., K.T., S.Y.); Cardiovascular Medicine, John Radcliffe Hospital, Oxford, UK (P.S.); University of Milano-Bicocca, Milano, Italy (G.M.); Hypertension Unit, Catholic University of Leuven, Leuven, Belgium (R.F.); Department of Clinical Medicine and Cardiovascular and Immunological Sciences,
| |
Collapse
|
96
|
Redon J, Fabia MJ. Efficacy in angiotensin receptor blockade: a comparative review of data with olmesartan. J Renin Angiotensin Aldosterone Syst 2009; 10:147-56. [PMID: 19651759 DOI: 10.1177/1470320309342735] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
A range of angiotensin II receptor blockers (ARB) is available, and analyses suggest there are differences between agents in terms of antihypertensive efficacy and 24-hour blood pressure control.This review assesses the data comparing olmesartan with other ARBs in terms of blood pressure reductions, goal achievement, 24-hour control and speed of onset. Olmesartan seems to have a more favourable efficacy profile relative to standard doses of the ARBs used in comparative studies; results consistent with the high degree of blockade of the angiotensin II type 1 receptor for olmesartan.Taken together, there might be differences between ARBs regarding their blood pressure lowering efficacy, and these results may provide further support of the benefits of olmesartan therapy since choice of an effective agent is crucial in antihypertensive therapy.
Collapse
Affiliation(s)
- Josep Redon
- Hypertension Clinic, Hospital Clínico Universitario, University of Valencia, Valencia, Spain.
| | | |
Collapse
|
97
|
Mansia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A. 2007 ESH‐ESC Guidelines for the management of arterial hypertension. Blood Press 2009; 16:135-232. [PMID: 17846925 DOI: 10.1080/08037050701461084] [Citation(s) in RCA: 238] [Impact Index Per Article: 15.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Giuseppe Mansia
- Clinica Medica, Ospedale San Gerardo, Universita Milano-Bicocca, Via Pergolesi, 33 - 20052 MONZA (Milano), Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
98
|
Gradman AH. Evolving understanding of the renin-angiotensin-aldosterone system: pathophysiology and targets for therapeutic intervention. Am Heart J 2009; 157:S1-6. [PMID: 19450719 DOI: 10.1016/j.ahj.2009.04.005] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Affiliation(s)
- Alan H Gradman
- Division of Cardiovascular Diseases, The Western Pennsylvania Hospital, Pittsburgh, PA 15224, USA.
| |
Collapse
|
99
|
|
100
|
Cukierman-Yaffe T, Gerstein HC, Anderson C, Zhao F, Sleight P, Hilbrich L, Jackson SHD, Yusuf S, Teo K. Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET/TRANSCEND research programme. Diabetes Res Clin Pract 2009; 83:387-93. [PMID: 19157618 DOI: 10.1016/j.diabres.2008.12.005] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/19/2008] [Revised: 11/25/2008] [Accepted: 12/02/2008] [Indexed: 11/15/2022]
Abstract
AIMS To assess the cross-sectional associations of the measures of glycemia and cognitive function in subjects at high cardiovascular risk. SETTING AND PATIENTS The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) and concurrent Telmisartan Randomized Assessment Study in ACE intolerant Subjects with Cardiovascular Disease (TRANSCEND) are multi-center, randomized, controlled investigations of different approaches to angiotensin receptor blockade in over 30,000 high CV risk subjects. Baseline data in both trials was used to analyze relationships between measures of glycemic control and cognition. OUTCOMES The univariate and multivariate relationships between diabetes status, fasting plasma glucose (FPG), and scores on the Mini-Mental State Examination (MMSE) were assessed. RESULTS In subjects with diabetes, the mean MMSE score was 0.4 units lower than in those without diabetes (P<0.0001). In all subjects, a 1 mmol/L higher FPG value was associated with a MMSE score that was 0.06 units lower (P<0.0001). The association persisted after adjustment for several cardiovascular risk factors. CONCLUSIONS Dysglycemia is a risk factor for impaired cognitive function in this broadly representative, high-risk study population. Prospective studies can more reliably discern temporal associations, including the effects of glucose lowering in this clinical group.
Collapse
|